Zhejiang Xianju Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is MIFEPRISTONE, with a corresponding US DMF Number 31873.
Remarkably, this DMF maintains an Active status since its submission on July 20, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 16, 2017, and payment made on August 21, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II